Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

IASO Approved to Start China Trials of Dual CAR-T for B-Cell Malignancies

publication date: Aug 2, 2021

ASO Bio, a Nanjing biotech, was approved to start clinical trials of its autologous CD19/CD22 CAR-T therapy for two indications. IASO said CT120’s dual-target design addresses tumor escape, a problem caused by target antigen loss that affects existing CAR-T therapies. The company expects CT120 will reduce relapse and improve survival. In-house developed CT120 will be tested to treat relapsed/refractory B-cell non-Hodgkin's lymphoma and relapsed/refractory B-cell acute lymphoblastic leukemia. In general, IASO targets B-cell malignancies. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China